WntResearch files a patent application expanding the commercial potential of Foxy-5
WntResearch is broadening its potential patent protection according to the commercial strategy by filing an international patent application that covers new stable compositions with high solubility of its candidate drug Foxy-5.
As an integral part of our commercial strategy, WntResearch has for the past year been working on different approaches for addressing the known limited solubility of Foxy-5 with the clear aim of identifying a new dosage form for further pivotal clinical studies and the future commercial launch. We have now succeeded in producing several new compositions of Foxy-5 which have improved solubility and excellent stability. We will further analyze the potential of these compositions during the coming year, in particular as regards assessing production scale-up and selecting the optimal future drug substance composition.
As a consequence of the new findings WntResearch has now filed a patent application which broadly covers these new compositions. Primarily, after grant of the patent, our commercial drug substance will be covered by patents for an extended time period (until 2041), thereby expanding the commercial potential of Foxy-5. Also, the new compositions may bring additional benefits to the patient and caregivers working with cancer.
“WntResearch is continuously working to improve drug substance characteristics with the possibility of identifying a new dosage form of Foxy-5 for further clinical studies and the future commercial launch. The results on which our new patent application is based, could strengthen and significantly extend the patent protection of our future commercial drug product” says WntResearch's CEO, Anders Rabbe.
For further information:
Anders Rabbe, acting CEO
Phone: +46 707 646 500
E-mail: anders.rabbe@wntresearch.com
This information was submitted for publication, through the agency of the contact person set out above, on January 17, 2022.
About WntResearch
WntResearch is a biotech company in oncology that develops new therapies intended to prevent the metastatic process. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumor cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 percent of all cancer-related deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer.
WntResearch is listed on the Spotlight Stock Market. For more information, please visit: www.wntresearch.com